A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

Phase 1 Completed 34 enrolled MedImmune LLC

RandomizedSingle-groupOpen-labelTreatment

To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.

Evaluation	Drug	Modality	Dose	Route
Subject	Anifrolumab	Monoclonal antibody	0.1 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	1 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Anifrolumab	Monoclonal antibody	20 mg/kg	Intravenous